SMAD3, prolifération cellulaire et métastases ganglionnaires dans le cancer du sein récepteurs hormonaux positifs
##plugins.themes.academic_pro.article.main##
Résumé
cancer du sein. Le statut des récepteurs hormonaux affecte le pronostic et la survie liés à ce cancer.
Onjectif : Le but de notre étude est de déchiffrer l’interaction potentielle entre le TGF-β et la distribution moléculaire des récepteurs hormonaux
(RH) dans 40 cas de cancer du sein.
Méthodes : Notre étude analyse les modèles d’expression de SMAD3 et des RH (ERα, ERβ et PR) dans 40 tissus mammaires tumoraux en
utilisant la technique qRT-PCR. Une évaluation de l’indice de prolifération Ki-67 et du statut HER2 par immunohistochimie a été réalisée.
Résultats : Une surexpression de SMAD3 est notée dans 13 cas (p= 0,003). Une corrélation statistiquement significative entre cette surexpression,
le grade histopronostique, le Ki-67 et les métastases ganglionnaires est également notée (p=0.003, p=0,001 et p= 0,01 respectivement). Nos
résultats montrent une association significative de l’expression de SMAD3 avec les sous-groupes (ERα+, ERβ+) et PR+ (p= 0.009 et p = 0,02
respectivement). L’expression des sous-groupes moléculaires (SMAD3+, ERα+, ERβ+) et (SMAD3+, PR+) est associée à des tumeurs agressives
(haut grade histopronostique : p = 0,02 et Ki 67 élevé : p = 0,01).
Conclusion : SMAD3 peut favoriser la prolifération cellulaire et les métastases ganglionnaires dans le cancer du sein RH +.
Mots-clés :
Cancer du sein, SMAD3, Récepteurs des œstrogènes, Récepteurs de la progestérone, Ki-67, Métastases ganglionnaires##plugins.themes.academic_pro.article.details##

Ce travail est disponible sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
Références
- (1) Steffensen C, Bak AM, Rubeck KZ & Jørgensen JO. Epidemiology of Cushing’s syndrome. Neuroendocrinology 2010; 92 (Suppl 1): 1–5.
- (2) Indholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen Let al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism 2001; 86: 117–123.
- (3) Arnardo ́ttir S & Sigurjonsdo ́ttir HA. The incidence and prevalence of Cushing’s disease may be higher than previously thought: results from a retrospective study in Iceland 1955 through 2009. Clinical Endocrinology 2011; 74: 792–793.
- (4) R.N.Clayton .Mortality in Cushing’s Disease. Neuroendocrinology 2010; 92(suppl 1):71–76.
- (5) Leah T. Braun, German Rubinstein, Stephanie Zopp, Frederick Vogel, Christine Schmid-Tannwald, Montserrat Pazos Escudero et al. Recurrence after pituitary surgery in adult Cushing’s disease: a systematic review on diagnosis and treatment. Endocrine 2020; 70:218–231.
- (6) Shimon I, Ram Z, Cohen ZR, Hadani M. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 2002; 51(1):57–61.
- (7) Krystallenia I, Alexandraki, Gregory A Kaltsas, Andrea M Isidori, Helen L Storr, Farhad Afshar, Ian Sabin et al. Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. European Journal of Endocrinology 2013; 168 :639–648
- (8) Toms GC, McCarthy MI, Niven MJ, Orteu CH, King TT & Monson JP. Predicting relapse after transsphenoidal surgery for Cushing’s disease. Journal of Clinical Endocrinology and Metabolism 1993; 76: 291–294.
- (9) S. Petersenn, A. Beckers, D. Ferone, A. van der Lely, J. Bollerslev, M. Boscaro et al. Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 2015; 172(6): 227–239.
- (10) D. Bochicchio, M. Losa, M. Buchfelder. Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J. Clin. Endocrinol. Metab. 1995; 80 (11): 3114–3120.
- (11) M. Fleseriu, A.H. Hamrahian, A.R. Hoffman, D.F. Kelly, L.Katznelson, American association of clinical endocrinologists and American college of endocrinology disease state clinical review: diagnosis of recurrence in Cushing disease. Endocr. Pract. 2016; 22(12): 1436–1448.
- (12) J.R. Lindsay, E.H. Oldfield, C.A. Stratakis, L.K. Nieman, The postoperative basal cortisol and CRH tests for prediction of longterm remission from Cushing’s disease after transsphenoidal surgery. J. Clin. Endocrinol. Metab. 2011; 96(7): 2057–2064.
- (13) N. Ironside, G. Chatain, D. Asuzu, S. Benzo, M. Lodish, S. Sharma, L. Nieman, C.A. Stratakis, R.R. Lonser, P. Chittiboina. Earlier post-operative hypocortisolemia may predict durable remission from Cushing’s disease. Eur. J. Endocrinol. 2018; 178(3): 255–263.
- (14) M. Mayberg, S. Reintjes, A. Patel, K. Moloney, J. Mercado, A. Carlson, J. Scanlan, F. Broyles, Dynamics of postoperative serum cortisol after transsphenoidal surgery for Cushing’s disease: implications for immediate reoperation and remission. J. Neurosurg. 2018; 129(5): 1268–1277.
- (15) Y. Liu, X. Liu, X. Hong, P. Liu, X. Bao, Y. Yao, B. Xing, Y. Li, Y. Huang, H. Zhu, L. Lu, R. Wang, M. Feng. Prediction of recurrence after transsphenoidal surgery for cushing’s disease: the use of machine learning algorithms. Neuroendocrinology 2019; 108 (3): 201–210.
- (16) J. Ramm-Pettersen, H. Halvorsen, J.A. Evang, P. Rønning, P.K. Hol, J. Bollerslev, J. Berg-Johnsen, E. Helseth. Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing’s disease. BMC Endocr. Disord. 2015; 15: 62.
- (17) L.B. Yap, H.E. Turner, C.B. Adams, J.A. Wass. Undetectable postoperative cortisol does not always predict long-term remission in Cushing’s disease: a single centre audit. Clin. Endocrinol. 2002; 56(1): 25–31.
- (18) A.M. Pereira, M.O. van Aken, H. van Dulken, P.J. Schutte, N.R. Biermasz, J.W. Smit, F. Roelfsema, J.A. Romijn. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing’s disease. J. Clin. Endocrinol. Metab. 2003 ; 88(12): 5858–5864.
- (19) C. Brichard, E. Costa, E. Fomekong, D. Maiter, C. Raftopoulos, Outcome of transsphenoidal surgery for cushing disease: a single-center experience over 20 Years. World Neurosurg 2018 ; 119 : e106–e117
- (20) A.M. Abu Dabrh, N.M. Singh Ospina, A. Al Nofal, W.H. Farah, P. Barrionuevo, M. Sarigianni, et al. Predictors of biochemical remission and recurrence after surgical and radiation treatments of Cushing disease: a systematic review and meta-analysis. Endocr. Pract 2016 ; 22 (4) : 466–475.
- (21) C.-H. Kuo, S.-R. Shih, H.-Y. Li, S.-C. Chen, P.-J. Hung, F.-Y. Tseng, T.-C. Chang. Adrenocorticotropic hormone levels before treatment predict recurrence of Cushing’s disease. J. Formos Med. Assoc. 2017 ; 116(6) : 441–447.
- (22) Langlois, F.; Lim, D.S.T.; Yedinak, C.G.; Cetas, I.; McCartney, S.; Cetas, J.; Dogan, A.; Fleseriu, M. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary 2017 ; 21 : 32–40.
- (23) Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions. Diagnostics (Basel) 2022 ; 12 : 977.